MaxCyte, Inc. (LON:MXCT - Get Free Report)'s share price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 206.79 ($2.77) and traded as low as GBX 160 ($2.14). MaxCyte shares last traded at GBX 165 ($2.21), with a volume of 41,396 shares.
MaxCyte Price Performance
The firm has a market cap of £220.18 million, a P/E ratio of -6.11 and a beta of 1.13. The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The firm has a 50-day simple moving average of GBX 203.90 and a 200-day simple moving average of GBX 277.66.
MaxCyte Company Profile
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Featured Articles
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
